Section Arrow
DNLI.NASDAQ
- Denali Therapeutics
Quotes are at least 15-min delayed:2026/04/21 21:21 EDT
Regular Hours
Last
 20.13
-0.41 (-2.00%)
Day High 
20.75 
Prev. Close
20.54 
1-M High
23.46 
Volume 
1.03M 
Bid
19.69
Ask
21.5
Day Low
19.94 
Open
20.5 
1-M Low
17.86 
Market Cap 
3.26B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 20.06 
20-SMA 20 
50-SMA 20.26 
52-W High 23.77 
52-W Low 12.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.97/-2.98
Enterprise Value
3.28B
Balance Sheet
Book Value Per Share
6.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
2.15
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.